China gene-editing trial: 2 boys improve, 1 dies, 1 withdraws

A Chinese gene-editing trial for a rare inherited disease in four boys produced mixed outcomes: two improved, one withdrew, and one died from a severe systemic reaction 81 hours after dosing. The death raises safety concerns for the therapy, though the small cohort limits conclusions. The trial's contradictory results underscore the high-risk, high-reward nature of gene-editing treatments.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works